Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.64 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.64 |
| ▸ | BLM | P54132 | 1/20 | 0.60 |
| ▸ | HPGD | P15428 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 3/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.59 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.59 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.59 |
| ▸ | DRD2 | P14416 | 1/20 | 0.59 |
| ▸ | HTR2A | P28223 | 1/20 | 0.59 |
| ▸ | RAB9A | P51151 | 1/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | USP2 | O75604 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4874422 | 0.88 | KMT2A (0.66) | MEN1KMT2AALDH1A1KDM4EKCNH2 | |
| SCHEMBL3688168 | 0.86 | MEN1 (0.64) | MEN1KMT2AALDH1A1KDM4EKCNH2 | |
| SCHEMBL28135954 | 0.86 | MEN1 (0.64) | MEN1KMT2AALDH1A1KDM4EKCNH2 | |
| SCHEMBL27943670 | 0.86 | MEN1 (0.64) | MEN1KMT2AALDH1A1KDM4EKCNH2 | |
| SCHEMBL10826271 | 0.85 | POLB (0.61) | MEN1KMT2AALDH1A1KDM4EHPGD | |
| SCHEMBL7129676 | 0.84 | HPGD (0.79) | MEN1KMT2AALDH1A1KDM4EKCNH2 | |
| SCHEMBL252026 | 0.84 | HPGD (0.79) | MEN1KMT2AALDH1A1KDM4EKCNH2 | |
| SCHEMBL10293583 | 0.84 | MEN1 (0.66) | MEN1KMT2AALDH1A1KDM4EKCNH2 | |
| SCHEMBL3694268 | 0.83 | BLM (0.67) | MEN1KMT2AALDH1A1KDM4EKCNH2 | |
| SCHEMBL3066080 | 0.83 | BLM (0.62) | MEN1KMT2AALDH1A1KDM4EKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1889836-B1 | NOVEL PYRIDINE DERIVATIVE AND PYRIMIDINE DERIVATIVE (3) | EISAI R&D MAN CO LTD (JP) | 2013-06-12 | — | — | EP | disclosed |
| EP-2058302-B1 | METHOD FOR PRODUCING PHENOXYPYRIDINE DERIVATIVE | EISAI R&D MAN CO LTD (JP) | 2013-04-17 | — | — | EP | disclosed |
| US-8288538-B2 | Pyridine derivatives and pyrimidine derivatives (3) | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-10-16 | — | — | US | disclosed |
| EP-1719762-B1 | NOVEL PYRIDINE DERIVATIVE AND PYRIMIDINE DERIVATIVE (1) | EISAI R&D MAN CO LTD (JP) | 2012-06-27 | — | — | EP | disclosed |
| US-7855290-B2 | N-[4-({2-[({4-[2-(Dimethylamino)ethyl]piperazin-1-yl}carbonyl)amino]pyridin-4-yl}oxy)-2-fluorophenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide; hepatocyte growth factor receptor (HGFR) inhibitors; antitumor, -carcinogenic, -metastasis agents | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-12-21 | — | — | US | disclosed |
| US-7790885-B2 | Process for preparing phenoxypyridine derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-09-07 | — | — | US | disclosed |
| US-20100075944-A1 | NOVEL PYRIDINE DERIVATIVES AND PYRIMIDINE DERIVATIVES (3) | MATSUSHIMA TOMOHIRO | 2010-03-25 | — | — | US | disclosed |
| EP-2058302-A1 | METHOD FOR PRODUCING PHENOXYPYRIDINE DERIVATIVE | Eisai R&D Management Co., Ltd. (JP) | 2009-05-13 | — | — | EP | disclosed |
| US-7531532-B2 | Hepatocyte growth factor receptor inhibitors; Antitumor agents, anticarcinogenic agents, angiogenesis inhibitors; pyrimidine derivatives like Pyrrolidine-1-carboxylic acid [6-(2-fluoro-4-{3-[2-(4-fluorophenyl)acetyl]thioureido}phenoxy)pyrimidin-4-yl]amide | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-05-12 | — | — | US | disclosed |
| US-20080319188-A1 | Novel pyridine derivatives and pyrimidine derivatives (3) | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2008-12-25 | — | — | US | disclosed |
| US-20080214815-A1 | Process for preparing phenoxypyridine derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2008-09-04 | — | — | US | disclosed |
| EP-1889836-A1 | NOVEL PYRIDINE DERIVATIVE AND PYRIMIDINE DERIVATIVE (3) | Eisai R&D Management Co., Ltd. (JP) | 2008-02-20 | — | — | EP | disclosed |
| US-20070270421-A1 | Novel pyridine Derivative and Pyrimidine Derivative (1) | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2007-11-22 | — | — | US | disclosed |
| EP-1719762-A1 | NOVEL PYRIDINE DERIVATIVE AND PYRIMIDINE DERIVATIVE (1) | Eisai Co., Ltd. (JP) | 2006-11-08 | — | — | EP | disclosed |
| US-20050277652-A1 | Novel pyridine derivative and pyrimidine derivative | EISAI CO., LTD. (JP) | 2005-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070270421-A1 | Novel pyridine Derivative and Pyrimidine Derivative (1) | HGF, MET, FLT1 | MEN1 3696/4885KMT2A 4095/4885ALDH1A1 557/4885 |
| US-20050277652-A1 | Novel pyridine derivative and pyrimidine derivative | HGF, MET, HDGF | MEN1 3870/4885KMT2A 4080/4885ALDH1A1 930/4885 |
| US-20080319188-A1 | Novel pyridine derivatives and pyrimidine derivatives (3) | HGF, MET, FLT4 | MEN1 3561/4885KMT2A 4189/4885ALDH1A1 899/4885 |
| US-20100075944-A1 | NOVEL PYRIDINE DERIVATIVES AND PYRIMIDINE DERIVATIVES (3) | HGF, MET, HDGF | MEN1 3868/4885KMT2A 4123/4885ALDH1A1 887/4885 |
| US-20080214815-A1 | Process for preparing phenoxypyridine derivatives | FIP1L1, SKP1, TET2 | MEN1 118/4885KMT2A 439/4885ALDH1A1 2045/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.